Mónica Sánchez-Cárdenas, Enzo Vásquez-Jiménez, Ricardo I Velázquez-Silva, Mario Vilatobá-Chapa, Benjamín Gómez-Navarro, Lucio O Sánchez-Macías, José M Rodríguez-Chagolla, Ignacio García-Juárez, Severo M Abraham-Mancilla, Luis E Morales-Buenrostro, Idalia Parra-Ávila, César Flores-Gama
{"title":"[COVID-19 in transplant recipients: Multicentric report of Mexican experience].","authors":"Mónica Sánchez-Cárdenas, Enzo Vásquez-Jiménez, Ricardo I Velázquez-Silva, Mario Vilatobá-Chapa, Benjamín Gómez-Navarro, Lucio O Sánchez-Macías, José M Rodríguez-Chagolla, Ignacio García-Juárez, Severo M Abraham-Mancilla, Luis E Morales-Buenrostro, Idalia Parra-Ávila, César Flores-Gama","doi":"10.24875/ACM.21000113","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Solid Organ Transplant recipients (SOTR) appear to be at particular high risk for critical COVID-19 due to immunosuppressive drugs and comorbidities. We report the first description of clinical course and short-term outcomes of kidney and liver transplant recipients with confirmed COVID-19 in Mexico. The objective of this paper was evaluate the clinical course of transplant patients with COVID-19 infection.</p><p><strong>Material and methods: </strong>We retrospectively evaluated SOTR (kidney and liver) over 18 years of age with confirmed diagnosis of COVID-19 from tertiary care centers in Mexico.</p><p><strong>Results: </strong>Data from 45 kidney transplant recipients were recorded. Median (IQR) age was 43 (IQR 25-70) years. Admission to hospital was required in 37 (75.5 %) patients, of which 8 (16.3%) were hospitalized at Intensive Care Unit (ICU). Acute kidney injury (AKI) stage was documented in 33 (67%) patients. The time of hospitalization was 8 (IQR 6-12) days. Six patients died (12.2%). Additionally, data from 10 liver transplant recipients were included. During their evolution, 5 / 10 required hospital admission and there were no deaths in this group.</p><p><strong>Conclusions: </strong>Transplant recipients show a higher fatality rate and complications from SARS-CoV-2 infection; more studies are needed to identify prognostic factors and effective anti-SARS-CoV-2 therapies.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":" ","pages":"66-74"},"PeriodicalIF":0.7000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de cardiologia de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/ACM.21000113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Solid Organ Transplant recipients (SOTR) appear to be at particular high risk for critical COVID-19 due to immunosuppressive drugs and comorbidities. We report the first description of clinical course and short-term outcomes of kidney and liver transplant recipients with confirmed COVID-19 in Mexico. The objective of this paper was evaluate the clinical course of transplant patients with COVID-19 infection.
Material and methods: We retrospectively evaluated SOTR (kidney and liver) over 18 years of age with confirmed diagnosis of COVID-19 from tertiary care centers in Mexico.
Results: Data from 45 kidney transplant recipients were recorded. Median (IQR) age was 43 (IQR 25-70) years. Admission to hospital was required in 37 (75.5 %) patients, of which 8 (16.3%) were hospitalized at Intensive Care Unit (ICU). Acute kidney injury (AKI) stage was documented in 33 (67%) patients. The time of hospitalization was 8 (IQR 6-12) days. Six patients died (12.2%). Additionally, data from 10 liver transplant recipients were included. During their evolution, 5 / 10 required hospital admission and there were no deaths in this group.
Conclusions: Transplant recipients show a higher fatality rate and complications from SARS-CoV-2 infection; more studies are needed to identify prognostic factors and effective anti-SARS-CoV-2 therapies.